Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 254-463-0 | CAS number: 39455-80-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Soluble tetra- and pentavalent vanadium substances failed to elicit any skin sensitising response in sensitisation studies according to Magnusson and Kligman (OECD 406).The studies by Haferkorn (2010a,b) are considered key studies on skin sensitisation and are used for classification.Positive human experience with any vanadium substance have not been reported. Based on read-across, ammonium sodium vanadium oxide is not assumed to have a potential for skin sensitisation.
Read across
Upon dissolution, vanadium substances transform inartificial body fluids, including PBS, sweat, gastric juice and lung fluid, predominantlyto the pentavalent form,exceptin artificial lysosomal fluid; here, even pentavalent forms are converted almost completely to tetravalent species already after a short period of time (for more information on in vitro bioaccessibility testing, please refer IUCLID section 7). Thus, it can be assumed that vanadium speciation in body fluids is controlled by the conditions of the respective medium but not by the vanadium source. Thus, read-across of skin sensitisation data from soluble tetra- and pentavalent vanadium substances is justified.
a) Ammonia/ammonium (i) is ubiquitous in the environment (air, soil and water) and as part of the natural nitrogen cycle intrinsically present in the human body due to a natural background in all dietary sources, and (ii) ammonia/ammonium is a normal constituent of all body fluids. The sources of endogenous ammonium include bacterial hydrolysis of urea and other nitrogenous compounds in the intestine, the purine-nucleotide cycle, amino acid transamination in skeletal muscle, and other metabolic processes in kidneys and liver. At physiological pH, it exists mainly as ammonium ion with reference serum levels just below 35 µmol/L. Any excess ammonia is excreted as urea, which is synthesised in the liver through the urea cycle.
b) Sodium is (i) ubiquitous in the environment (air, soil and water), (ii) a key nutrient and intrinsically present in the human body due to a natural background in all dietary sources, and (iii) a normal constituent of all body fluids and a main blood mineral. Sodium is necessary for humans to maintain the balance of the physical fluids system and is required for nerve and muscle functioning. In consequence, because of the intrinsic nature of sodium as endogenous physiological compound, any skin sensitising effect of sodium is not to be expected.
As consequence, any effects observed in human health studies based on the vanadium ion and not on the cation. Nevertheless, a study conducted with sodium metavanadate is included as weight of evidence that results also in no sensitising potential of the substance.
Migrated from Short description of key information:
Soluble penta- and tetravalent vanadium substances tested negative (i.e. not sensitising) in skin sensitisation studies according to Magnusson and Kligman (OECD 406). A justification for using the Magnusson and Kligman design instead of the LLNA is provided as attached document below. Ammonium sodium vanadium oxide is not considered to have a sensitisation potential.
Justification for selection of skin sensitisation endpoint:
The studies by Haferkorn (2010a,b) are considered key studies on skin sensitisation and used for classification.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
- Migrated from Short description of key information:
Exposure to ammonium sodium vanadium oxide has not been reported to induce immune responses in vanadium industry workers, and occupational asthma or reduced lung function have not been diagnosed in vanadium and vanadium substances producing facilities.
Justification for classification or non-classification
Based on the outcome of sensitisation studies with soluble tetra- and pentavalent vanadium forms according to Magnusson and Kligman, it can be concluded that ammonium sodium vanadium oxide does not have a sensitisation potential and therefore must not need to be classified and labelled according to Directive 67/548/EEC and to Regulation (EC) 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.